Theranexus (EPA:ALTHX)

PRESS RELEASE

published on 07/10/2025 at 18:00, 1 year 2 months ago

THERANEXUS PUBLISHES ITS CASH POSITION AS OF 30 JUNE 2025
Theranexus, a biopharmaceutical company, reports a cash position of €2.1M as of 30 June 2025, with upcoming funds and financial visibility through Q2 2026. CEO discusses collaborations and strategic progress. H1 2025 results expected on September 25, 2025

Cash Position Biopharmaceutical Financial Publication Theranexus Rare Neurological Diseases
BRIEF

published on 05/13/2025 at 18:05, 1 year 3 months ago

Theranexus and BBDF reveal promising results for Batten-1

Theranexus Batten-1 BBDF Batten Disease Visual Acuity
PRESS RELEASE

published on 05/13/2025 at 18:00, 1 year 3 months ago

THERANEXUS AND BEYOND BATTEN DISEASE FOUNDATION ANNOUNCE STRONG POSITIVE REAL-WORLD DATA SUPPORTING BATTEN-1 EFFICACY FOR THE TREATMENT OF BATTEN DISEASE
Theranexus and BBDF announce new data supporting Batten-1 (miglustat) efficacy for CLN3 disease treatment. Results show significant preservation of visual acuity in treated patients over 12 months. Real-world analysis aligns with Phase 3 trial design

Theranexus Batten-1 BBDF Visual Acuity CLN3 Disease
BRIEF

published on 04/29/2025 at 19:05, 1 year 4 months ago

Theranexus: 2024 Annual Review and New Perspectives

Financial Results Partnerships Theranexus Batten-1 Grants
PRESS RELEASE

published on 04/29/2025 at 19:00, 1 year 4 months ago

THERANEXUS PUBLISHES ITS 2024 FULL-YEAR RESULTS, PRESENTS ITS PROGRESS REPORT AND CLOSES ITS EQUITY LINE
Theranexus publishes financial results for 2024 & cash position as of March 31, 2025, presents progress report & plans for Batten-1 drug candidate. Board approves accounts. Continues strategic partnerships & developments

Financial Results Strategic Partnerships Clinical Trials Theranexus Batten-1
BRIEF

published on 03/06/2025 at 18:05, 1 year 6 months ago

Modification of the Theranexus liquidity contract

Liquidity Contract AMF PORTZAMPARC Theranexus Rare Neurological Diseases
BRIEF

published on 01/31/2025 at 18:10, 1 year 7 months ago

Half-yearly report on Theranexus' liquidity contract with Portzamparc

Liquidity Contract Transactions PORTZAMPARC Half-yearly Report Theranexus
BRIEF

published on 01/30/2025 at 18:05, 1 year 7 months ago

Theranexus Strengthens its Treasury and Develops its Partnerships

Treasury Theranexus Neurological Diseases Exeltis Partnership Bpifrance Financing
PRESS RELEASE

published on 01/30/2025 at 18:00, 1 year 7 months ago

THERANEXUS PUBLISHES ITS CASH POSITION AS OF 31 DECEMBER 2024 AND PRESENTS ITS PROGRESS REPORT
Theranexus announces cash position of €4.0 M as of 29 January 2025, strengthening financial outlook. Biopharmaceutical company progressing on rare neurological disease treatments, including Niemann-Pick and Gaucher diseases

Cash Position Biopharmaceutical Financial Outlook Theranexus Neurological Diseases
BRIEF

published on 01/23/2025 at 18:20, 1 year 7 months ago

Theranexus Unveils 2025 Financial Calendar

Financial Calendar Biopharmaceutical Theranexus Neurological Diseases 2025 Schedule

Published on 09/12/2026 at 02:35, 1 day 9 hours ago

Gamma Resources Announces Extension of Private Placement Closing Date
Published on 09/11/2026 at 23:00, 1 day 12 hours ago

Rio Grande Resources Engages Machai Capital for Investor Outreach
Published on 09/11/2026 at 22:05, 1 day 13 hours ago

Usha Resources Announces Leadership Transition
Published on 09/11/2026 at 21:25, 1 day 14 hours ago

Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 1 day 18 hours ago

Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors

View all ACCESSWIRE

Published on 09/12/2026 at 17:50, 17 hours 49 minutes ago

New Delhi Marks UN Day for South-South Cooperation with Push to Scale Dryland Innovation Across the Global South
Published on 09/12/2026 at 07:30, 1 day 4 hours ago

NAGRAVISION Secures Formula 1 Content for RTL Croatia and PRO PLUS Slovenia
Published on 09/11/2026 at 22:15, 1 day 13 hours ago

Amrize Appoints Mario Gross as President of Building Envelope
Published on 09/11/2026 at 22:10, 1 day 13 hours ago

Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Published on 09/11/2026 at 19:44, 1 day 15 hours ago

DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031

View all EQS

Published on 09/11/2026 at 07:00, 2 days 4 hours ago

Transparency notification by Baltisse Group
Published on 09/11/2026 at 07:00, 2 days 4 hours ago

BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/10/2026 at 19:30, 2 days 16 hours ago

Availability of the 2026 Interim Financial Report
Published on 09/10/2026 at 07:00, 3 days 4 hours ago

2026 H1 results and new identity
Published on 09/09/2026 at 18:45, 3 days 16 hours ago

Successful launch of a €500 million bond issue

View all LES ECHOS COMFI WIRE

News